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al. found a 70 percent reduction in the risk of venous
thromboembolism without excessive bleeding when
the first dose of enoxaparin was given 12 to 24 hours
postoperatively following hip replacement.2 Thus,
plastic surgeons must still rely on the literature in
other areas or on personal experience, as opposed to
empirical evidence, to base their clinical decisions
regarding the choice of agent, dosage, and timing of
administration.
Ultimately, decisions with respect to thrombopro-
phylaxis in microsurgical breast reconstruction should
be guided by considerations such as drug availability in
a given institution, cost, ease of administration, and
patient comfort, in addition to the clinically relevant
outcomes of thromboprophylaxis. A multicenter pro-
spective trial powered to detect differences in venous
thromboembolism events with different regimens of
low-molecular-weight heparin prophylaxis, controlling
for various dosages and timing of administration in
women undergoing microsurgical breast reconstruc-
tion, would be welcome. Such a trial would be able to
highlight significant increases in the incidence of ma-
jor bleeding associated with various low-molecular-
weight heparin agents, variable doses, and frequency of
administration. Such evidence could provide definitive
information in a population where bleeding can have
devastating consequences.
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Total Muscular Implant Coverage in Alloplastic
Breast Reconstruction
Sir:
I t was with great pleasure that we read the interestingarticle by Elliott et al.,1 recently published in this
Journal, and we would like to congratulate the authors
on their study. The authors described the use of the
“scarless” latissimus dorsi flap to provide total well-vas-
cularized coverage to implant or tissue expander in
conjunction with pectoralis major muscle.
The traditional tissue expander or implant place-
ment requires complete muscular coverage by ele-
vating both the pectoralis major and the serratus
anterior. We agree with the authors that it is impor-
tant to have vascularized and adequate coverage
when implanting devices, but we believe that sacrifice
of a large muscle such as the latissimus dorsi is not
always justified, especially if radiotherapy has not
been performed. The latissimus dorsi should be used
for implant coverage in case of previous radiotherapy
to reduce the risk of capsular contracture2; other-
wise, the serratus anterior combined with the pec-
toralis major muscle usually provides full muscular
coverage to the device, especially in the event of a
partially inflated tissue expander (Fig. 1). Partial cov-
erage with the pectoralis only is not recommended
because of the possibility of expander exposure or
migration. Excellent results in nonirradiated and
thin patients can be achieved with complete muscu-
lar pocket by means of the pectoralis major and
serratus anterior muscles (Fig. 2). Furthermore, dis-
secting the serratus can be performed more easily
and more quickly than the latissimus dorsi muscle.
While raising the serratus, care should be taken at the
junction between the pectoralis and serratus muscu-
lature, where there are only tiny muscular fibers and
sheath. Use of the serratus anterior muscle also
has less impact on daily activities and is associated
with lower morbidity than sacrifice of the latissimus
dorsi muscle.
An option gaining popularity is anteromedial cov-
erage with the pectoralis and lateral coverage with acel-
lular dermal matrix.3,4 This obviates the need for ser-
ratus elevation and might make subsequent expansion
less painful. Concerning the use of acellular dermal
matrix instead of muscle for implant coverage, we be-
lieve that we should take into account the biological
cost of the latissimus dorsi muscle sacrifice and the
economic cost of acellular dermal matrix. In any event,
despite an increased rate of infection and seroma with
use of acellular dermal matrix,5,6 there is an increasing
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interest in use of this material for alloplastic breast
reconstruction.
Finally, we wonder whether the scarless latissimus
dorsi might require wider undermining compared with
the standard latissimus dorsi procedure, with the sub-
sequent increased risk of donor-site seroma formation.
Furthermore, as a large muscle has been elevated, pro-
viding total muscular device coverage, immediate per-
manent implant placement should be preferred rather
than a tissue expander, particularly in cases of skin- or
nipple-sparing mastectomies. This would bring effec-
tive reduced cost, sparing the patient the second step
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Fig. 1. The pectoralis major muscle is elevated to establish part of
the pocket for tissue expander insertion. The serratus anterior is el-
evated to allow for inferolateral coverage of the device. The partially
inflated tissue expander is placed in the pocket with the serratus
approximated to the lateral edge of the pectoralis major muscle.
Fig. 2. Preoperative (above) and postoperative (below) appear-
ance of a patient who underwent right expander replacement
with anatomical cohesive silicone gel implant and contralateral
augmentation mammaplasty.
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Reply: Total Muscular Implant Coverage in
Alloplastic Breast Reconstruction
Sir:
I thank Dr. Salval and colleagues for their thoughtful
comments in response to the article entitled “The Scar-
less Latissimus Dorsi Flap for Full Muscle Coverage in
Device-Based Immediate Breast Reconstruction: An
Autologous Alternative to Acellular Dermal Matrix.”
First, it is important to say that this technique is offered
as another option for breast reconstruction using de-
vice-based techniques. Of course, it is not the only
choice, but in our hands, it has proved very successful
in the thinner patient.
Dr. Salval and colleagues comment that the latissi-
mus dorsi flap is not always justified, especially if ra-
diotherapy has not been performed. I agree completely
and, indeed, there is no one technique that is best for
all patients. However, with or without previous irradi-
ation, I have found the latissimus/pectoralis combina-
tion to increase the naturalness of the result in the
thinner patient who, after mastectomy, has very little
cutaneous and subcutaneous tissue coverage. Recon-
struction with implants after irradiation is often prob-
lematic; we try to avoid it.
The serratus anterior combined with the pectoralis
major muscle has been advocated since the 1980s for
full muscle coverage of an underlying device. However,
our use of this technique in the 1980s revealed it to be
deficient for various reasons—in fact, for the very rea-
sons suggested by the respondents. The weakest part of
this “coverage” is at the junction between the pectoralis
and serratus musculature. There is truly no union of
these two muscles in that location and, particularly in
a thin patient, it is very difficult to get adequate cov-
erage at that point. In addition, the serratus anterior
muscle is chiefly located posterior to the posterior ax-
illary line; thus, the portion of the muscle with which
one is dealing to cover the anterior device is very thin
and has terminating fibers as it approaches the pecto-
ralis major muscle. This makes full muscle coverage of
the device relatively deficient. As pointed out in their
beautiful case, the serratus/pectoralis combination can
be successful, and when it can be, it is an excellent
choice. I have just found that in a large majority of cases
it is not as reliable or as thick of a coverage as I would
like. That is why my colleagues and I turned to the
latissimus in combination with the pectoralis.
Numerous studies have documented the low mor-
bidity associated with the latissimus muscle. Although
studies are not as extensive for the scarless latissimus,
I believe that this technique will have less morbidity
than the myocutaneous technique. Indeed, the donor
defect is barely detectable, and motor limitations have
been very few. I suspect that the serratus can be dis-
sected more quickly than the latissimus. I have found
that the latissimus technique takes approximately 45
minutes on each side. This probably is a little longer
than for the serratus, but there is guaranteed thick
muscle coverage over the lower lateral device.
The authors correctly point out that acellular dermal
matrix has become an increasingly popular choice for
device coverage. As mentioned in the article, my col-
leagues and I have not yet been able to compare the
biological and economic costs between the latissimus
and acellular dermal matrix. However, as also men-
tioned in the article, we have not been able to clinically
determine whether one technique is better than the
other in terms of the postoperative result.
The scarless latissimus actually requires less under-
mining than that needed to harvest the full muscle of
a myocutaneous flap. My colleagues and I harvest ap-
proximately 80 percent of the muscle and only need
that much coupled with the pectoralis major to provide
full muscle coverage. It is not our choice in general to
choose a permanent implant at the time of the first
operation but, instead, to use a tissue expander. The
technique of tissue expander is, of course, preferred to
ensure the safety of the skin, not because of deficient
muscle coverage. Thus, our choice for a tissue ex-
pander is based on skin survival, not on issues with
regard to the musculature. Nonetheless, there are, of
course, patients with whom we are comfortable with
regard to their skin and in whom an immediate implant
is used.
The incidence of seroma in our series is less than 6
percent. This compares favorably with the reported
range of 20 to 70 percent in a recent article concerning
latissimus myocutaneous flaps.1
Once again, I thank Dr. Salval and his colleagues for
their thoughtful comments. I continue to advocate the
scarless latissimus for the appropriate patient.
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